Attached files

file filename
10-K - 10-K 2020 - Ovid Therapeutics Inc.ovid-10k_20201231.htm
EX-31.2 - EX-31.2 - Ovid Therapeutics Inc.ovid-ex312_9.htm
EX-31.1 - EX-31.1 - Ovid Therapeutics Inc.ovid-ex311_11.htm
EX-23.1 - EX-23.1 - Ovid Therapeutics Inc.ovid-ex231_7.htm
EX-10.25 - EX-10.25 - Ovid Therapeutics Inc.ovid-ex1025_869.htm
EX-10.19 - EX-10.19 - Ovid Therapeutics Inc.ovid-ex1019_727.htm
EX-10.18 - EX-10.18 - Ovid Therapeutics Inc.ovid-ex1018_728.htm
EX-10.17 - EX-10.17 - Ovid Therapeutics Inc.ovid-ex1017_726.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Ovid Therapeutics Inc. (the “Company”) for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his or her knowledge:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 15, 2021

 

By

/s/ Jeremy M. Levin

 

Jeremy M. Levin

Chief Executive Officer

(Principal Executive Officer)

 

Date: March 15, 2021

 

By

/s/ Timothy Daly

 

Timothy Daly
Executive Vice President, Finance and Corporate Controller

(Principal Financial Officer and Principal Accounting Officer)